Menu
Currency
GWAS Study

Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors.

Melin BS, Barnholtz-Sloan JS, Wrensch MR et al.

28346443 PubMed ID
GWAS Study Type
30659 Participants
245 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

MB
Melin BS
BJ
Barnholtz-Sloan JS
WM
Wrensch MR
JC
Johansen C
ID
Il'yasova D
KB
Kinnersley B
OQ
Ostrom QT
LK
Labreche K
CY
Chen Y
AG
Armstrong G
LY
Liu Y
EJ
Eckel-Passow JE
DP
Decker PA
LM
Labussière M
IA
Idbaih A
HK
Hoang-Xuan K
DS
Di Stefano AL
MK
Mokhtari K
DJ
Delattre JY
BP
Broderick P
GP
Galan P
GK
Gousias K
SJ
Schramm J
SM
Schoemaker MJ
FS
Fleming SJ
HS
Herms S
HS
Heilmann S
NM
Nöthen MM
WH
Wichmann HE
SS
Schreiber S
SA
Swerdlow A
LM
Lathrop M
SM
Simon M
SM
Sanson M
AU
Andersson U
RP
Rajaraman P
CS
Chanock S
LM
Linet M
WZ
Wang Z
YM
Yeager M
WJ
Wiencke JK
HH
Hansen H
ML
McCoy L
RT
Rice T
KM
Kosel ML
SH
Sicotte H
AC
Amos CI
BJ
Bernstein JL
DF
Davis F
LD
Lachance D
LC
Lau C
MR
Merrell RT
SJ
Shildkraut J
AF
Ali-Osman F
SS
Sadetzki S
SM
Scheurer M
SS
Shete S
LR
Lai RK
CE
Claus EB
OS
Olson SH
JR
Jenkins RB
HR
Houlston RS
BM
Bondy ML
Chapter II

Abstract

Summary of the research findings

Genome-wide association studies (GWAS) have transformed our understanding of glioma susceptibility, but individual studies have had limited power to identify risk loci. We performed a meta-analysis of existing GWAS and two new GWAS, which totaled 12,496 cases and 18,190 controls. We identified five new loci for glioblastoma (GBM) at 1p31.3 (rs12752552; P = 2.04 × 10-9, odds ratio (OR) = 1.22), 11q14.1 (rs11233250; P = 9.95 × 10-10, OR = 1.24), 16p13.3 (rs2562152; P = 1.93 × 10-8, OR = 1.21), 16q12.1 (rs10852606; P = 1.29 × 10-11, OR = 1.18) and 22q13.1 (rs2235573; P = 1.76 × 10-10, OR = 1.15), as well as eight loci for non-GBM tumors at 1q32.1 (rs4252707; P = 3.34 × 10-9, OR = 1.19), 1q44 (rs12076373; P = 2.63 × 10-10, OR = 1.23), 2q33.3 (rs7572263; P = 2.18 × 10-10, OR = 1.20), 3p14.1 (rs11706832; P = 7.66 × 10-9, OR = 1.15), 10q24.33 (rs11598018; P = 3.39 × 10-8, OR = 1.14), 11q21 (rs7107785; P = 3.87 × 10-10, OR = 1.16), 14q12 (rs10131032; P = 5.07 × 10-11, OR = 1.33) and 16p13.3 (rs3751667; P = 2.61 × 10-9, OR = 1.18). These data substantiate that genetic susceptibility to GBM and non-GBM tumors are highly distinct, which likely reflects different etiology.

12,469 European ancestry cases, 18,190 European ancestry controls.

Chapter III

Study Statistics

Key metrics and study information

30659
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.S., Australia, France, Germany, China, Israel, Denmark, Sweden, U.K.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.